All hepatitis D virus articles
-
News Huayunuo approval positions China at forefront of viral hepatitis innovation, says GlobalData
Huahui Health has recently secured conditional approval from China for Huayunuo (Libevitug Injection), marking it as the first domestically developed monoclonal antibody (mAb) drug for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis.